ETV6::ABL1 融合：从骨髓增生性肿瘤中被忽视的小克隆到白血病转化中的主要角色

IF 3.4 3区医学 Q1 PATHOLOGY

Virchows Archiv Pub Date : 2024-07-27 DOI:10.1007/s00428-024-03881-x

Hyun-Woo Lee, Min-Seung Park, Boram Kim, Chul Won Jung, Hee-Jin Kim, Hyun-Young Kim

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

ETV6::ABL1 fusion: from overlooked minor clone in myeloproliferative neoplasm to major player in leukemic transformation

查看原文本刊更多论文

ETV6::ABL1 fusion: from overlooked minor clone in myeloproliferative neoplasm to major player in leukemic transformation

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.